Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sarah Gheuens Sells 500 Shares of Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Sarah Gheuens sold 500 shares of the company’s stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $37.52, for a total transaction of $18,760.00. Following the transaction, the insider owned 54,645 shares in the company, valued at $2,050,280.40. The trade was a 0.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sarah Gheuens also recently made the following trade(s):

• On Wednesday, October 21st, Sarah Gheuens sold 1,489 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $37.53, for a total transaction of $55,882.17.
• On Tuesday, August 4th, Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $30.48, for a total value of $914,400.00.

Agios Pharmaceuticals Trading Down 0.5%

Shares of NASDAQ:AGIO traded down $0.19 during trading on Friday, hitting $37.00. 920,048 shares of the stock were exchanged, compared to its average volume of 1,213,961. The company has a market cap of $2.21 billion, a PE ratio of -5.28 and a beta of 0.63. Agios Pharmaceuticals, Inc. has a 12-month low of $22.24 and a 12-month high of $46.00. The company has a fifty day moving average price of $33.41 and a two-hundred day moving average price of $32.79.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). The firm had revenue of $44.75 million during the quarter, compared to analysts’ expectations of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. Equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -5.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Inspire Investing LLC increased its position in Agios Pharmaceuticals by 4.7% during the third quarter. Inspire Investing LLC now owns 19,130 shares of the biopharmaceutical company’s stock worth $636,000 after purchasing an additional 861 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Agios Pharmaceuticals by 1,714.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock valued at $62,723,000 after purchasing an additional 1,782,457 shares during the last quarter. Tidal Investments LLC boosted its holdings in shares of Agios Pharmaceuticals by 12.0% in the 2nd quarter. Tidal Investments LLC now owns 16,100 shares of the biopharmaceutical company’s stock valued at $597,000 after purchasing an additional 1,724 shares during the last quarter. Engineers Gate Manager LP grew its stake in shares of Agios Pharmaceuticals by 86.4% during the 2nd quarter. Engineers Gate Manager LP now owns 53,912 shares of the biopharmaceutical company’s stock valued at $2,001,000 after buying an additional 24,992 shares during the period. Finally, Integrated Wealth Concepts LLC purchased a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at $47,000.

Analysts Set New Price Targets

A number of equities research analysts have commented on AGIO shares. Bank of America increased their target price on Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a “buy” rating in a report on Monday, September 21st. Truist Financial decreased their price objective on Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating on the stock in a research note on Wednesday, October 7th. JPMorgan Chase & Co. increased their price objective on Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Citigroup lifted their price objective on Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $41.50.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.